Financial
FY2025 adjusted EBITA SEK 4.88bn, a 14.0% adjusted margin; organic growth 4.9%.
Band uses the adjusted margin; reported net sales and profit not yet captured.
Getinge
HQ Sweden · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Strong
Customer rating
No reviews yet
Financial health
Band: StrongListed: GETI-B.ST
FY2025 adjusted EBITA SEK 4.88bn, a 14.0% adjusted margin; organic growth 4.9%.
Band uses the adjusted margin; reported net sales and profit not yet captured.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | — | — | — | — | Getinge |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
No adverse media involving Getinge found in HSH's search of the last 24 months.
Cyber & information governance
No confirmed data breaches, cyber incidents or regulator action involving Getinge found in HSH's search of the last 24 months. Unverified claims on ransomware leak-site trackers are not included. NHS DSPT status not yet checked.
Regulatory & clinical safety
Jun 2026: Getinge subsidiary Maquet Cardiovascular began a US FDA Class II recall of 205 VasoView HemoPro 2 vessel-harvesting devices exposed to an out-of-specification sterilisation dose at a contract steriliser; users were told to quarantine affected units.
Contract performance
Oct 2025: Aneurin Bevan University Health Board extended its rental of a Getinge mobile decontamination unit at Royal Gwent Hospital (about £87.6k ex VAT, to Apr 2026) by single tender waiver. No disputes or terminations found in HSH's search of the last 24 months.
Competitors
No competitors linked yet.